{
    "title": "Genetic variants and clinical determinants affecting the response to 5-Fluorouracil-based treatment in Chilean patients with advanced colorectal cancer",
    "pmcid": "PMC12331468",
    "summary": "This study identifies genetic variants in the TYMS, DPYD, and GSTP1 genes among others, which influence the response to 5-Fluorouracil (5-FU)-based chemotherapy in Chilean patients with advanced colorectal cancer. A total of 82 patients were analyzed, revealing significant associations between specific genotypes and adverse drug reactions (ADRs). Noteworthy findings include that the G allele of GSTP1 was protective against neuropathy but increased mucositis risk, while the deletion genotype of TYMS offered protection against hematological adverse reactions. The study develops predictive models for anemia and pain, emphasizing the potential for personalized medicine in optimizing chemotherapy safety.",
    "study_parameters": [
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82.0,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients receiving 5-FU-based chemotherapy",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.012",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.147,
            "Confidence Interval Start": 0.007,
            "Confidence Interval Stop": 0.991,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82.0,
            "Study Controls": null,
            "Characteristics": "5-FU treatment causing mucositis",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.036",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.27,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82.0,
            "Study Controls": null,
            "Characteristics": "C allele of DPYD variant rs1801265 linked to neuropathy risk",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.05",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 4.58,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82.0,
            "Study Controls": null,
            "Characteristics": "TYMS deletion genotype associated with protection against hematological adverse reactions",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.029,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82.0,
            "Study Controls": null,
            "Characteristics": "3R genotype of TYMS 5'UTR linked to skin and subcutaneous tissue disorders",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.029",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 6.4,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82.0,
            "Study Controls": null,
            "Characteristics": "Multivariate model predicting anemia",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.027",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82.0,
            "Study Controls": null,
            "Characteristics": "Multivariate model predicting pain with MTHFR and ERCC2 variants",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.01",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        }
    ],
    "var_drug_ann": [
        {
            "Variant/Haplotypes": "rs1801265",
            "Gene": "DPYD",
            "Drug(s)": "5-fluorouracil",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The C allele of DPYD (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05).",
            "Sentence": "The C allele is associated with increased risk of neuropathy in patients receiving 5-fluorouracil treatment.",
            "Alleles": "C",
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "response to",
            "Comparison Allele(s) or Genotype(s": "T/T",
            "Comparison Metabolizer types": "normal metabolizer",
            "Specialty Population": "",
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:colorectal cancer",
            "Multiple drugs And/or": "",
            "Multiple phenotypes or diseases And/or": "",
            "Citations": [
                "The C allele of DPYD (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05).",
                "Further analysis of ungrouped ADRs indicated a higher risk of neuropathy in patients carrying the C allele of the DPYD rs1801265 polymorphism (codominant model T/C genotype OR = 30.0, p-value = 0.0049, dominant model OR = 4.583, p-value = 0.05).",
                "This study aimed to establish a correlation between the patient's genotype and the risk of ADR in Chilean advanced CRC patients."
            ]
        },
        {
            "Variant/Haplotypes": "rs1695",
            "Gene": "GSTP1",
            "Drug(s)": "5-fluorouracil",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).",
            "Sentence": "The G allele is associated with decreased risk of neuropathy but increased risk of mucositis in patients receiving 5-fluorouracil treatment.",
            "Alleles": "G",
            "Metabolizer types": "",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased,increased",
            "PD/PK terms": "response to",
            "Comparison Allele(s) or Genotype(s": "A",
            "Comparison Metabolizer types": "",
            "Specialty Population": "",
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:colorectal cancer",
            "Multiple drugs And/or": "",
            "Multiple phenotypes or diseases And/or": "",
            "Citations": [
                "The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).",
                "Among the 16 variants analyzed in 82 patients, key findings included: The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).",
                "The G allele of the GSTP1 rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy."
            ]
        },
        {
            "Variant/Haplotypes": "rs11280056",
            "Gene": "TYMS",
            "Drug(s)": "5-fluorouracil",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The TYMS deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001).",
            "Sentence": "The deletion genotype is associated with decreased risk of hematological adverse reactions in patients receiving 5-fluorouracil treatment.",
            "Alleles": "del/del",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "response to",
            "Comparison Allele(s) or Genotype(s": "",
            "Comparison Metabolizer types": "",
            "Specialty Population": "",
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:colorectal cancer",
            "Multiple drugs And/or": "",
            "Multiple phenotypes or diseases And/or": "",
            "Citations": [
                "The TYMS deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001).",
                "We identified a protective correlation between the 6bp deletion of the TYMS 3'UTR region (rs11280056) and a lower risk of gastrointestinal and hematological disorders in chemotherapy patients.",
                "When analyzing the risk of grouped ADR while considering only severe reactions (Grade III-IV), we found that only the TYMS 3'UTR 6bp deletion (rs11280056) was the only polymorphism associated with a lower risk of severe hematological disorders (dominant model OR = 0,098, CI 95% 0.013 - 0.441, p-value =0.005)."
            ]
        },
        {
            "Variant/Haplotypes": "rs45445694",
            "Gene": "TYMS",
            "Drug(s)": "5-fluorouracil",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The 3R genotype of TYMS 5'UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029).",
            "Sentence": "The 3R genotype is associated with increased risk of skin and subcutaneous tissue disorders in patients receiving 5-fluorouracil treatment.",
            "Alleles": "3R/3R",
            "Metabolizer types": "",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "response to",
            "Comparison Allele(s) or Genotype(s": "",
            "Comparison Metabolizer types": "",
            "Specialty Population": "",
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:colorectal cancer",
            "Multiple drugs And/or": "",
            "Multiple phenotypes or diseases And/or": "",
            "Citations": [
                "On the other hand, the 3R genotype of TYMS 5'UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029).",
                "This study provides a foundation for developing pharmacogenetic-based predictive models for adverse reactions associated with 5-FU, including...skin and subcutaneous tissue disorders.",
                "A retrospective nested case-control study was conducted on 82 advanced colorectal cancer patients. Sixteen genetic variants were analyzed to assess their association with adverse reactions and their severity using logistic regression."
            ]
        }
    ],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "rs1695",
            "Gene": "GSTP1",
            "Drug(s)": "5-fluorouracil",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).",
            "Sentence": "GSTP1 rs1695 is associated with decreased neuropathy and increased mucositis risk when treated with 5-fluorouracil in Chilean patients with colorectal cancer.",
            "Alleles": "G/A",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": null,
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "neuropathy, mucositis",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in colorectal cancer patients",
            "Population Phenotypes or diseases": "colorectal cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": null,
            "Variant Annotation ID_norm": null,
            "Citations": [
                "The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).",
                "This study provides a foundation for developing pharmacogenetic-based predictive models for adverse reactions associated with 5-FU, including neuropathy, mucositis, and hematological and skin toxicities.",
                "Patients were categorized into two groups: exposed (carriers of the risk allele) and non-exposed (carriers of the non-risk allele)."
            ]
        },
        {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "rs1801265",
            "Gene": "DPYD",
            "Drug(s)": "5-fluorouracil",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The C allele of DPYD (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05).",
            "Sentence": "DPYD rs1801265 is associated with increased neuropathy risk when treated with 5-fluorouracil in Chilean patients with colorectal cancer.",
            "Alleles": "C/T",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": null,
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "neuropathy",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in colorectal cancer patients",
            "Population Phenotypes or diseases": "colorectal cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": null,
            "Variant Annotation ID_norm": null,
            "Citations": [
                "The C allele of DPYD (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05).",
                "The C allele of DPYD (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05).",
                "This study aimed to establish a correlation between the patient's genotype and the risk of ADR in Chilean advanced CRC patients."
            ]
        },
        {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "rs11280056",
            "Gene": "TYMS",
            "Drug(s)": "5-fluorouracil",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The TYMS deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001).",
            "Sentence": "TYMS rs11280056 is associated with decreased risk of hematological toxicity when treated with 5-fluorouracil in Chilean patients with colorectal cancer.",
            "Alleles": "del/ins",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": null,
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "hematological adverse reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in colorectal cancer patients",
            "Population Phenotypes or diseases": "colorectal cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": null,
            "Variant Annotation ID_norm": null,
            "Citations": [
                "The TYMS deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001).",
                "The results showed that the *TYMS* 3'UTR 6bp deletion (rs11280056) was positively correlated with a lower risk of gastrointestinal and hematological disorders in chemotherapy patients.",
                "Among the 16 variants analyzed in 82 patients, key findings included: The *TYMS* deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001)."
            ]
        },
        {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "rs45445694",
            "Gene": "TYMS",
            "Drug(s)": "5-fluorouracil",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The 3R genotype of TYMS 5'UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029).",
            "Sentence": "TYMS rs45445694 is associated with increased risk of skin and subcutaneous tissue disorders when treated with 5-fluorouracil in Chilean patients with colorectal cancer.",
            "Alleles": "3R/2R",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": null,
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "skin and subcutaneous tissue disorders",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in colorectal cancer patients",
            "Population Phenotypes or diseases": "colorectal cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": null,
            "Variant Annotation ID_norm": null,
            "Citations": [
                "On the other hand, the 3R genotype of TYMS 5'UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029).",
                "This study provides a foundation for developing pharmacogenetic-based predictive models for adverse reactions associated with 5-FU, including... skin and subcutaneous tissue toxicities.",
                "A total of 82 patients with advanced CRC were recruited from BTUCH, INC, and FALP for this study. The characteristics of the participants are summarized in Table 1."
            ]
        }
    ],
    "var_fa_ann": [
        {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "DPYD rs1801265 C at risk",
            "Gene": "DPYD",
            "Drug(s)": "5-Fluorouracil",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "C allele linked to higher risk of neuropathy (OR = 4.58; p = 0.05)",
            "Sentence": "The C allele of DPYD (rs1801265) is associated with increased risk of neuropathy when treated with 5-Fluorouracil compared to non-C allele carriers.",
            "Alleles": "C",
            "Metabolizer types": null,
            "Comparison Allele(s) or Genotype(s)": "T/T",
            "Assay type": null,
            "Cell type": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Functional terms": "risk of",
            "Gene/gene product": null,
            "Citations": [
                "The C allele of DPYD (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05).",
                "Further analysis of ungrouped ADRs indicated a higher risk of neuropathy in patients carrying the C allele of the DPYD rs1801265 polymorphism (codominant model T/C genotype OR = 30.0, p-value = 0.0049, dominant model OR = 4.583, p-value = 0.05).",
                "Pharmacogenomic research has revealed that a myriad of proteins is involved in the pharmacokinetics and pharmacodynamics of 5-FU and L-OHP. Genetic variability within a population can lead to alterations in the genes encoding these proteins affecting individual responses to FP-based chemotherapy."
            ]
        },
        {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "GSTP1 rs1695 G allele",
            "Gene": "GSTP1",
            "Drug(s)": "5-Fluorouracil",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "G allele protective against neuropathy but increases mucositis risk (OR = 2.27; p = 0.036)",
            "Sentence": "The G allele of GSTP1 (rs1695) is associated with increased risk of mucositis when treated with 5-Fluorouracil compared to A/A genotype.",
            "Alleles": "G",
            "Metabolizer types": null,
            "Comparison Allele(s) or Genotype(s)": "A/A",
            "Assay type": null,
            "Cell type": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Functional terms": "risk of",
            "Gene/gene product": null,
            "Citations": [
                "The G allele of *GSTP1* (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).",
                "The presence of neuropathy, included in the nervous system disorders, occurred in 37.8% (n: 31) of patients."
            ]
        },
        {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "TYMS deletion genotype rs11280056",
            "Gene": "TYMS",
            "Drug(s)": "5-Fluorouracil",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Deletion genotype conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001)",
            "Sentence": "The TYMS deletion genotype (rs11280056) is associated with decreased risk of hematological adverse reactions when treated with 5-Fluorouracil compared to normal alleles.",
            "Alleles": "del",
            "Metabolizer types": null,
            "Comparison Allele(s) or Genotype(s)": "INS/INS",
            "Assay type": null,
            "Cell type": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "decreased",
            "Functional terms": "risk of",
            "Gene/gene product": null,
            "Citations": [
                "The TYMS deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001).",
                "The 6bp deletion in the 3'UTR (rs11280056) was associated with a decreased risk of gastrointestinal and hematological ADRs.",
                "When analyzing the risk of grouped ADR while considering only severe reactions (Grade III-IV), we found that only the TYMS 3'UTR 6bp deletion (rs11280056) was the only polymorphism associated with a lower risk of severe hematological disorders (dominant model OR = 0,098, CI 95% 0.013 - 0.441, p-value =0.005)."
            ]
        },
        {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "TYMS 5'UTR 3R genotype rs45445694",
            "Gene": "TYMS",
            "Drug(s)": "5-Fluorouracil",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "3R genotype associated with increased risk of skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029)",
            "Sentence": "The 3R genotype of TYMS 5'UTR (rs45445694) is associated with increased risk of skin and subcutaneous tissue disorders when treated with 5-Fluorouracil compared to other genotypes.",
            "Alleles": "3R/3R",
            "Metabolizer types": null,
            "Comparison Allele(s) or Genotype(s)": "2R/2R + 2R/3R",
            "Assay type": null,
            "Cell type": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Functional terms": "risk of",
            "Gene/gene product": null,
            "Citations": [
                "On the other hand, the 3R genotype of TYMS 5'UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029).",
                "The findings suggest that genotyping genes involved in the metabolism of 5-FU... may provide valuable insight into the factors contributing to ADRs in CRC patients.",
                "The C allele of DPYD (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05)."
            ]
        },
        {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "MTHFR rs1801131 C allele",
            "Gene": "MTHFR",
            "Drug(s)": "5-Fluorouracil",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "C allele linked to increased risk of nervous system disorders; protective against pain (‚óè).",
            "Sentence": "The C allele of MTHFR (rs1801131) is associated with increased risk of nervous system disorders while being protective against pain when treated with 5-Fluorouracil compared to other genotypes.",
            "Alleles": "C",
            "Metabolizer types": null,
            "Comparison Allele(s) or Genotype(s)": "A/A",
            "Assay type": null,
            "Cell type": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Functional terms": "risk of",
            "Gene/gene product": null,
            "Citations": [
                "Furthermore, we found a direct correlation between the C allele of the *MTHFR* rs1801131 polymorphism and an increased risk of nervous system disorders in chemotherapy patients, while also showing that it was correlated with a lower risk of pain\".",
                "The protective association of the *MTHFR* rs1801131 C allele against pain was evident, with statistical significance observed in our logistic regression models (p-value = 0.035).",
                "The analysis of polymorphisms in *MTHFR* in our cohort, comprising 82 advanced colorectal cancer patients, indicated that the C allele is significantly linked to specific adverse drug reactions during treatment with 5-Fluorouracil."
            ]
        }
    ]
}